Opella Healthcare Poland Sp. z o.o. is the Polish subsidiary of Opella, a global consumer healthcare group that originated from the former Consumer Healthcare division of Sanofi and now operates as an independent company focused on non-prescription medicines and self-care solutions. In Poland, Opella Healthcare manages a portfolio of over-the-counter medicines, food supplements and medical devices across key therapeutic areas including allergy, pain relief, digestive health, cough and cold, mental health and vitamins, minerals and supplements. Its product range includes internationally recognized brands such as Allegra for allergy, as well as other OTC and VMS brands from the Opella global portfolio that are registered and marketed on the Polish market, distributed via pharmacies, drugstore chains and other retail channels. The company serves as the central entity for consumer healthcare operations within a broader Central and Eastern Europe cluster, working alongside Opella entities in Hungary, Czech Republic, Slovakia, Romania and other markets to coordinate regional strategies. Geographically, Opella Healthcare Poland focuses on the domestic market while contributing to regional initiatives and cross-border projects in CEE. It leverages the global Opella group's reach across more than 100 countries, supported by dedicated manufacturing sites and R&D and innovation centers. Strategically, Opella Healthcare Poland positions itself as a branded consumer healthcare player committed to making self-care simple and accessible, concentrating on strong brand building, medical and patient education, responsible promotion and sustainability, within the global Opella framework of “Health in Your Hands.”
Headquarters
Ul. Marcina Kasprzaka 6
Warsaw; Mazowieckie;
Postal Code: 01-211
Contact Details: Purchase the Opella Healthcare Poland Sp. z o.o. report to view the information.
Website: https://www.opella.com/en
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service